By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a recent study.